Keywords: Boehringer Ingelheim, Viramune, Flomax, Impax, Patents, USA
Boehringer Ingelheim launches co-pay rebate program for Viramune in USA; settles with Impax over Flomax
Article | 7 October 2009
Independent German drugmaker Boehringer Ingelheim’s US subsidiary has launched the Viramune (nevirapine) tablets/oral suspension Co-Pay Savings Program, a special program that will allow patients to save up to $50 on their health insurance co-payment on every monthly refill of a Viramune prescription for up to one year. Any patient with a prescription for the HIV/AIDS drug who has health insurance coverage requiring a patient co-payment is eligible for the program.
“There is a growing reliance by patients on co-pay and patient assistance programs offered by pharmaceutical companies and this rebate program makes it easier for HIV/AIDS patients to benefit,” said Albert Ros, executive vice president of sales and marketing at Boehringer Ingelheim Pharmaceuticals. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
